EGFR and non-small cell lung carcinoma: As mentioned above, the cost-effectiveness of NGS also depends on the number of samples available for each run, and should not just be used for EGFR, ALK, and ROS1 assessment, but to look for all the mandatory biomarkers of NS-NSCLC stipulated in the international guidelines [56,57].